Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)
China flag China · Delayed Price · Currency is CNY
16.80
-0.49 (-2.83%)
Nov 17, 2026, 3:00 PM CST

Aurisco Pharmaceutical Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
1,6661,6891,4721,2541,001800.46
Other Revenue
8.738.733.678.597.232.9
1,6741,6971,4761,2631,008803.36
Revenue Growth
3.07%15.02%16.89%25.24%25.48%11.36%
Cost of Revenue
776.2697.29631.38564.22495.51408.64
Gross Profit
898.21,000844.36698.32512.57394.72
Selling, General & Admin
307.42297.25300.7270.49175.27136
Research & Development
152.32153.39146.34136.89117.2669.35
Other Operating Expenses
14.529.327.387.937.636.7
Operating Expenses
479.64467.62457.96419.48304.36211.96
Operating Income
418.56532.56386.4278.83208.21182.76
Interest Expense
-9.2-34.71-15.78-2.74-1.01-0.64
Interest & Investment Income
8.4419.9118.3148.254.418.94
Currency Exchange Gain (Loss)
-9.83-9.8318.243.5824.86-7.44
Other Non Operating Income (Expenses)
-51.262.25-0.89-1.62-0.630.79
EBT Excluding Unusual Items
356.7510.18406.28326.31235.84184.41
Gain (Loss) on Sale of Investments
3.194.442.25--1.19-
Gain (Loss) on Sale of Assets
0.06-0.55-0.41-1.53-1.5-0.4
Asset Writedown
-0.23-0.23-0.17---
Other Unusual Items
9.264.45-1.044.37.598
Pretax Income
368.99518.3407.39329.08240.75192.01
Income Tax Expense
52.4669.0952.640.0132.4723.73
Earnings From Continuing Operations
316.53449.21354.79289.07208.28168.28
Minority Interest in Earnings
---0.352.690.43
Net Income
316.53449.21354.79289.42210.96168.71
Net Income to Common
316.53449.21354.79289.42210.96168.71
Net Income Growth
-25.44%26.61%22.59%37.19%25.04%7.31%
Shares Outstanding (Basic)
403401399408406402
Shares Outstanding (Diluted)
410408399408406402
Shares Change
2.75%2.44%-2.21%0.48%1.00%7.31%
EPS (Basic)
0.791.120.890.710.520.42
EPS (Diluted)
0.771.100.890.710.520.42
EPS Growth
-27.44%23.60%25.35%36.54%23.81%0%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
31.9271.42-207.8780.13-49.82-49.04
Free Cash Flow Per Share
0.080.17-0.520.20-0.12-0.12
Dividend Per Share
0.3400.3400.2900.2200.1600.130
Dividend Growth
17.24%17.24%31.82%37.50%23.08%8.33%
Gross Margin
53.64%58.92%57.22%55.31%50.85%49.13%
Operating Margin
25.00%31.37%26.18%22.09%20.65%22.75%
Profit Margin
18.90%26.46%24.04%22.92%20.93%21.00%
Free Cash Flow Margin
1.91%4.21%-14.09%6.35%-4.94%-6.11%
EBITDA
565.35651.87469.05352.98273.15234.22
EBITDA Margin
33.76%38.40%31.78%27.96%27.10%29.15%
D&A For EBITDA
146.79119.382.6574.1564.9451.47
EBIT
418.56532.56386.4278.83208.21182.76
EBIT Margin
25.00%31.37%26.18%22.09%20.65%22.75%
Effective Tax Rate
14.22%13.33%12.91%12.16%13.49%12.36%
Revenue as Reported
460.421,6971,4761,2631,008803.36
Advertising Expenses
-38.5356.7233.73--